S. L. Luykx‐de Bakker

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.

Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells.

T. D. de Gruijl, P. Pohlmann, E. van der Wall, 2003, European journal of cancer.

Rapid Stereology Based Quantitative Immunohistochemistry of Dendritic Cells in Lymph Nodes: A Methodological Study

P. V. van Diest, G. Meijer, H. Pinedo, 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

Dendritic cells: a novel therapeutic modality.

T. D. de Gruijl, J. Wagstaff, H. Pinedo, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors1

D. Curiel, T. D. de Gruijl, J. Buter, 2002, The Journal of Immunology.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

E. Vellenga, B. Biemond, A. A. van de Loosdrecht, 2011, British journal of haematology.